In a patient with breast cancer after TCH (docetaxel, carboplatin, trastuzumab) neoadjuvant chemotherapy who has residual disease, is repeat immunohistochemistry for estrogen receptor, progesterone receptor, and HER2 (human epidermal growth factor receptor 2) warranted?

Repeat IHC Testing After TCH Neoadjuvant Chemotherapy with Residual Disease

Routine repeat IHC testing for ER, PR, and HER2 is not currently recommended when the initial biopsy showed positive results (HER2-positive in your TCH-treated patient), but reassessment should be strongly considered in specific clinical scenarios that may alter treatment decisions.

Primary Recommendation Based on Guidelines

The 2015 Modern Pathology international working group guidelines 1 provide clear algorithmic guidance:

When Routine Retesting is NOT Recommended:

• Positive ER/PR/HER2 on pretreatment core biopsy (which applies to your HER2-positive patient)
• Rationale: The majority of patients show no change in marker expression
• Important caveat: Uncertainty exists whether conversion should inform future adjuvant therapy choices
• Notable exception: Loss of HER2 amplification following neoadjuvant trastuzumab has been associated with worse outcomes, though the independent prognostic value remains unclear

When Reassessment SHOULD Be Considered:

Despite the general recommendation against routine retesting in HER2-positive cases, you should consider repeat IHC in these specific situations:

1. No response to therapy - If residual disease shows minimal or no treatment effect, retesting may reveal tumor heterogeneity
2. Heterogeneous tumor or multiple tumors with different morphologies on resection
3. Clinician request for retesting - When treatment decisions hinge on receptor status
4. If HER2 status is reassessed and found discordant, perform both IHC and ISH testing

Clinical Context and Discordance Rates

The evidence shows meaningful discordance rates that justify selective retesting 1:

• ER discordance: 13-18% (meta-analyses)
• PR discordance: 26-32% (meta-analyses)
• HER2 discordance: 6-9% (meta-analyses)

Critical finding: Trastuzumab-containing regimens (like your TCH) may increase the rate of HER2-negative conversion 1. Research data 2 confirms this, showing HER2 status changes in 7.1% of cases, predominantly switching from positive to negative.

Practical Algorithm for Your Patient

Given your patient received TCH (trastuzumab-containing) with residual disease:

Step 1: Assess treatment response pathologically

• If robust response with minimal residual disease → routine retesting not necessary
• If poor response or extensive residual disease → proceed to Step 2

Step 2: Evaluate for high-risk features warranting retesting:

• Heterogeneous morphology in residual tumor
• Multiple distinct tumor foci with variable appearance
• Clinical consideration of changing treatment strategy based on receptor status

Step 3: If retesting performed and shows HER2 conversion to negative:

• This has prognostic implications (associated with worse outcome 1)
• Consider this in adjuvant treatment planning
• May influence decision regarding continuation of HER2-targeted therapy

Impact on Treatment Decisions

The 2023 ASCO-CAP HER2 guideline update 3 emphasizes the importance of accurate HER2 assessment for treatment eligibility, particularly for newer agents like trastuzumab deruxtecan in the metastatic setting. While this primarily addresses HER2-low disease, it underscores that receptor status directly impacts therapeutic options.

Research evidence 2, 4 demonstrates that:

• ER conversion (negative to positive): Occurs in 6-8% of cases, often weakly positive (ER-low)
• HER2 conversion (positive to negative): Occurs in 7-23% depending on whether anti-HER2 therapy was used
• These conversions could influence decisions about endocrine therapy or continued HER2-targeted therapy

Common Pitfalls to Avoid

1. Don't assume stability: While most tumors maintain receptor status, the subset that converts may have different biology and prognosis
2. Technical factors matter: Causes of discordance include technical artifacts, misinterpretation, intratumoral heterogeneity, and therapy-induced changes 1
3. Weakly positive results: Conversions from negative to positive often yield low-level expression (ER 1-10%, HER2 IHC 1+), requiring careful interpretation 2, 4
4. Clinical trial context: If your patient is enrolled in a clinical trial, retesting is mandatory 1

Bottom Line for Clinical Practice

For your HER2-positive patient with residual disease after TCH: Routine retesting is not standard practice, but given the trastuzumab-associated risk of HER2 conversion and its prognostic implications, consider retesting if (1) there was poor treatment response, (2) tumor morphology appears heterogeneous, or (3) the results would meaningfully alter adjuvant treatment decisions, particularly regarding continuation of HER2-targeted therapy or addition of endocrine therapy for hormone receptor-positive disease.